Budweg Jeffery, Ahmed Mustafa M, Vilaro Juan R, Al-Ani Mohammad A, Aranda Juan M, Guo Yi, Li Ang, Patel Sandip, Parker Alex M
Department of Medicine, Division of Cardiology, University of Florida, Gainesville, FL, USA.
Department of Medicine, Division of Cardiology, Statistics, University of Florida, Gainesville, FL, USA.
Am Heart J Plus. 2024 Jul 30;45:100436. doi: 10.1016/j.ahjo.2024.100436. eCollection 2024 Sep.
Diuretics are the mainstay of maintaining and restoring euvolemia in the management of heart failure. Loop diuretics are often preferred, however, combination diuretic therapy (CDT) with a thiazide diuretic is often used to overcome diuretic resistance and increase diuretic effect. We performed an analysis of the GUIDE-IT study to assess all-cause mortality and time to first hospitalizations in patients necessitating CDT.
Patients from the GUIDE-IT dataset were stratified by their requirement for CDT with a thiazide to achieve euvolemia. A total of 894 patients were analyzed, 733 of which were treated with loop diuretics alone vs 161 used either chlorothiazide or metolazone in addition to loop diuretics. Kaplan-Meir curves were derived with log-rank -values to evaluate for differences between the groups.
There was no significant difference in all-cause mortality regardless of CDT utilization status (mean survival of 612.704 days vs 603.326 days, = 0.083). On subgroup analysis, there was no significant difference in all-cause mortality amongst those using loop diuretics compared to CDT in the BNP-guided therapy group, (mean survival time 576.385 days vs 620.585 days, = 0.0523), nor the control group (614.1 days vs 588.9 days; = 0.5728). Time to first hospitalization was reduced in all using CDT compared to loop diuretics alone (280.5 days vs 407.2 days, < 0.0001). On subgroup analysis, both the BNP-guided group as well as the control group had reduced time to first hospitalization in the CDT group compared to those who did not require CDT (BNP group: 287.503 days vs 402.475 days, ≤0.0001; control group 248.698 days vs 399.035 days, = 0.0009).
Use of CDT is associated with earlier time to hospitalization, though no association was identified with increased all-cause mortality. Further prospective studies are likely needed to determine the true risk and benefits of combination diuretic therapy.
利尿剂是心力衰竭管理中维持和恢复血容量正常的主要药物。尽管常常首选袢利尿剂,但噻嗪类利尿剂联合利尿疗法(CDT)常用于克服利尿剂抵抗并增强利尿效果。我们对GUIDE-IT研究进行了分析,以评估需要CDT的患者的全因死亡率和首次住院时间。
来自GUIDE-IT数据集的患者根据实现血容量正常所需的噻嗪类CDT需求进行分层。总共分析了894例患者,其中733例仅接受袢利尿剂治疗,161例除袢利尿剂外还使用了氯噻嗪或美托拉宗。采用对数秩值得出Kaplan-Meir曲线,以评估组间差异。
无论CDT使用情况如何,全因死亡率均无显著差异(平均生存期分别为612.704天和603.326天,P = 0.083)。亚组分析显示,在BNP指导治疗组中,使用袢利尿剂的患者与使用CDT的患者相比,全因死亡率无显著差异(平均生存时间分别为576.385天和620.585天,P = 0.0523),对照组也是如此(分别为614.1天和588.9天;P = 0.5728)。与单独使用袢利尿剂相比,所有使用CDT的患者首次住院时间均缩短(分别为280.5天和407.2天,P < 0.0001)。亚组分析显示,与不需要CDT的患者相比,BNP指导组和对照组中CDT组的首次住院时间均缩短(BNP组:分别为287.503天和402.475天,P≤0.0001;对照组:分别为248.698天和399.035天,P = 0.0009)。
使用CDT与更早的住院时间相关,但未发现与全因死亡率增加有关。可能需要进一步的前瞻性研究来确定联合利尿疗法的真正风险和益处。